Wilmington PharmaTech announced a $50 million investment to expand its Delaware campus for active pharmaceutical ingredient (API) manufacturing. Newark, Delaware-based Wilmington PharmaTech said the expansion more than doubles its current API reactor capacity. It adds two new 10,000-liter reactor suites to increase commercial-scale manufacturing capabilities. This supports growing demand for high-quality, U.S.-based manufacturing as the…